Can apolipoproteins and complement factors be biomarkers of Alzheimer's disease?

Current Alzheimer Research

Volumn 9, Issue 8, 2012, Pages 935-943

  Manral, Pallavi ^a   Sharma, Pratibha ^a   Hariprasad, Gururao ^a   Chandralekha, C ^a   Tripathi, Manjari ^a   Srinivasan, Alagiri ^a  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

Biomarkers; CSF; Diagnosis; Pathways

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; APOLIPOPROTEIN E; CLUSTERIN; COMPLEMENT COMPONENT C4B; HEMOPEXIN;

ADULT; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; GEL ELECTROPHORESIS; HUMAN; MALE; MASS SPECTROMETRY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTEOMICS;

ALZHEIMER DISEASE; APOLIPOPROTEINS; BIOLOGICAL MARKERS; COMPLEMENT SYSTEM PROTEINS; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HUMANS; MIDDLE AGED; TANDEM MASS SPECTROMETRY;

EID: 84867703154     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/156720512803251110     Document Type: Article

References (63)

1. DeKosky ST, Marek K. Looking backward to move forward: early detection of neurodegenerative disorders. Science 302: 830-34 (2003).
2. Chong MS, Sahadevan S. Preclinical Alzheimer's disease: diagnosis and prediction of progression. Lancet Neurol 4: 576-9 (2005).
3. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease-report of the NINCDS-ADRDA Work group under the auspices of Department of Health and Human Services task force on Alzheimer's disease. Neurology 34: 939-44 (1984).
4. Maarouf CL, Andacht TM, Kokjohn TA, Castaño EM, Sue LI, Beach TG, et al. Proteomic analysis of Alzheimer's disease cerebrospinal fluid from neuropathologically diagnosed subjects. Curr Alzheimer Res 6: 399-406 (2009).
5. Sihlbom C, Davidsson P, Sjögren M, Wahlund LO, Nilsson CL. Structural and quantitative Comparison of Cerebrospinal Fluid Glycoproteins in Alzheimer's disease Patients and Healthy Individual. Neurochem Res 33: 1332-40 (2008).
6. Brechlin P, Jahn O, Steinacker P, Cepek L, Kratzin H, Lehnert S, et al. Cerebrospinal fluid-optimized two-dimensional difference gel electrophoresis (2D-DIGE) facilitates the differential diagnosis of Creutzfeldt-Jakob disease. Proteomics 8: 4357-66 (2008).
7. Bai S, Liu S, Guo X, Qin Z, Wang B, Li X, et al. Proteome analysis of biomarkers in the cerebrospinal fluid of neuromyelitis optica patients. Mol Vis 15:1638-48 (2009).
8. Fang Q, Strand A, Law W, Faca VM, Fitzgibbon MP, Hamel N, et al. Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics 8: 451-66 (2009).
9. BioGRID: http://www.thebiogrid.org/viewdocument.php? documentid= 6 last modified on 28 July 2010 and Accessed on August 1, 2010.
10. Cytoscape for Biological Interaction Network: http://www.cytoscape.org Cytoscape v.2.7.0, Updated: 2010-03-31 and Accessed on: April 16, 2010.
11. Jing Gao, Alex Ade, David States, CCMB/NCIBI University of Michigan, MiMI v.3.01, Release Date: 2010-04-29 and Accessed on July 13, 2010.
12. BIND (Biomolecular Interaction Network Database): http://www.bind.ca BIND database updated to BOND Biomolecular Object Network Databank, Unleashed Bioinformatics, May 26, 2010, Accessed on July 14, 2010.
13. DIP: http://dip.doe-mbi.ucla.edu/termsofuse.html Database of Interacting Proteins, Updated January 10, 2010 and Accessed on July 14, 2010.
14. IPI: http://www.ebi.ac.uk/IPI/IPIhelp.html Updated September 2007, Accessed on July 14, 2010.
15. Keshava Prasad TS, Goel R, Kandasamy K, Keerthikumar S, Kumar S, Mathivanan S, et al. Human Protein Reference Database--2009 update. Nucleic Acids Res 37, Database issue, D767-72 (2009) [PubMed], Accessed on July 14, 2010.
16. CCSB-HI1: http://ccsb.dfci.harvard.edu/web/www/ccsb Updated-20-10-2005 and Accessed on July 14, 2010.
17. IntAct: http://www.ebi.ac.uk/intact/site/index.jsf, IntAct molecular interaction database (2010), Accessed on July 14, 2010.
18. KEGG: Kyoto Encyclopedia of Genes and Genomeshttp:// www.genome.jp/keg-Accessed on July 28, 2010.
19. Gelissen IC, Hochgrebe T, Wilson MR, Easterbrook-Smith SB, Jessup W, Dean RT, et al. Apolipoprotein J (clusterin) induces cholesterol export from macrophage-foam cells: a potential antiatherogenic function? Biochem J 331 (Pt 1): 231-37 (1998).
20. Calero M, Rostagno A, Matsubara E, Zlokovic B, Frangione B, Ghiso J. Apolipoprotein J (clusterin) and Alzheimer's disease. Microsc Res Tech 50: 305-15 (2000).
21. Yerbury JJ, Stewart EM, Wyatt AR, Wilson MR. Quality control of protein folding in extracellular space. EMBO Rep 6: 1131-36 (2005).
22. Zlokovic BV, Martel CL, Matsubara E, McComb JG, Zheng G, McCluskey RT, et al. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proc Natl Acad Sci U S A 93: 4229-34 (1996).
23. Yerbury JJ, Poon S, Meehan S, Thompson B, Kumita JR, Dobson CM, et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J 21: 2312-22 (2007).
24. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, et al. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-99 (2009).
25. Holtzman DM, Bales KR, Wu S, Bhat P, Parsadanian M, Fagan AM, et al. Expression of human apolipoprotein E reduces amyloidbeta deposition in a mouse model of Alzheimer's disease. J Clin Invest 103: R15-21(1999).
26. DeMattos RB, Cirrito JR, Parsadanian M, May PC, O'Dell MA, Taylor JW, et al. ApoE and clusterin cooperatively suppress Abeta levels and deposition: evidence that ApoE regulates extracellular Abeta metabolism in vivo. Neuron 41: 193-202 (2004).
27. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, et al. Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89: 10016-20 (1992).
28. Shen Y, Lue L, Yang L, Roher A, Kuo Y, Strohmeyer R, et al. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci Lett 305: 165-8 (2001).
29. Veerhuis R, Janssen I, Hack CE, Eikelenboom P. Early complement components in Alzheimer's disease brains. Acta Neuropathol 91: 53-60 (1996).
30. Hye A, Lynham S, Thambisetty M, Causevic M, Campbell J, Byers HL, et al. Proteome based plasma biomarkers for Alzheimer's disease. Brain 129 (Pt 11): 3042-50 (2006).
31. Strohmeyer R, Shen Y, Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res Mol Brain Res 81: 7-18 (2000).
32. Bradt BM, Kolb WP, Cooper NR. Complement-dependent proinflammatory properties of the Alzheimer's disease betapeptide. J Exp Med 188: 431-38 (1998).
33. Mauk MR, Rosell FI, Lelj-Garolla B, Moore GR, Mauk AG. Metal ion binding to human hemopexin. Biochemistry 44: 1864-71 (2005).
34. Tolosano E, Hirsch E, Patrucco E, Camaschella C, Navone R, Silengo L, et al. Defective recovery and severe renal damage after acute hemolysis in hemopexin-deficient mice. Blood 94: 3906-14 (1999).
35. Morello N, Tonoli E, Logrand F, Fiorito V, Fagoonee S, Turco E, et al. Hemopexin affects iron distribution and ferritin expression in mouse brain. J Cell Mol Med 13: 4192-4204 (2009).
36. Smith MA, Hirai K, Hsiao K, Pappolla MA, Harris PL, Siedlak SL, et al. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 70: 2212-5 (1998).
37. Roher AE, Maarouf CL, Sue LI, Hu Y, Wilson J, Beach TG. Proteomics-derived cerebrospinal fluid markers of autopsyconfirmed Alzheimer's disease. javascript:ALget(this, 'jour', 'Biomarkers.'); Biomarkers 14: 493-501(2009).
38. Foidart M, Eiseman J, Engel WK, Adornato BT, Liem HH, Muller-Eberhard U. Effect of heme administration on hemopexin metabolism in the rhesus monkey. J Lab Clin Med 100: 451-60 (1982).
39. Kitamura Y. Functional activation of glial cells in early and delayed episodes of the brain damage. Nihon Yakurigaku Zasshi 111: 147-56 (1998).
40. Thambisetty M, Simmons A, Velayudhan L, Hye A, Campbell J, Zhang Y, et al. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry 67: 739-48 (2010).
41. Akuffo EL, Davis JB, Fox SM, Gloger IS, Hosford D, Kinsey EE, et al. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13: 618-36 (2008).
42. Veerhuis R. Histological and direct evidence for the role of complement in the neuroinflammation of AD. Curr Alzheimer Res 8: 34-58 (2011).
43. Hoarau JJ, Krejbich-Trotot P, Jaffar-Bandjee MC, Das T, Thon-Hon GV, Kumar S, et al. Activation and control of CNS innate immune responses in health and diseases: a balancing act finely tuned by neuroimmune regulators (NIReg). CNS Neurol Disord Drug Targets 10: 25-43 (2011).
44. Zheng X, Zhang X, Sun H, Feng B, Li M, Chen G, et al. Protection of renal ischemia injury using combination gene silencing of complement 3 and caspase 3 genes. Transplantation 82: 1781-86 (2006).
45. Lai CS, Preisler J, Baum L, Lee DH, Ng HK, Hugon J, et al. Low molecular weight Abeta induces collapse of endoplasmic reticulum. Mol Cell Neurosci 41: 32-43 (2009).
46. Coskun P, Wyrembak J, Schriner S, Chen HW, Marciniack C, Laferla F, et al. A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta 1820: 552-64 (2012).
47. Yasojima K, Schwab C, McGeer EG, McGeer PL. Up-regulated production and activation of the complement system in Alzheimer's disease brain. Am J Pathol 154: 927-36 (1999).
48. Kataria J, Rukmangadachar LA, Hariprasad G, O J, Tripathi M, Srinivasan A. Two dimensional difference gel electrophoresis analysis of cerebrospinal fluid in tuberculous meningitis patients. J Proteomics 74: 2194-203 (2011).
49. Rukmangadachar LA, Kataria J, Hariprasad G, Samantaray JC, Srinivasan A. Two-dimensional difference gel electrophoresis (DIGE) analysis of sera from visceral leishmaniasis patients. Clin Proteomics 8: 4 (2011).
50. Antúnez C, Boada M, López-Arrieta J, Moreno-Rey C, Hernández I, Marín J, et al. Genetic association of complement receptor 1 polymorphism rs3818361 in Alzheimer's disease. Alzheimers Dement 7: e124-90 (2011).
51. Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, Pasquier F, et al. Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 17: 223-33 (2012).
52. Finehout EJ, Franck Z, Lee KH. Complement protein isoforms in CSF as possible biomarkers for neurodegenerative disease. Dis Markers 21: 93-101 (2005).
53. Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Novel Aß Isoforms in Alzheimeŕs Disease-Their Role in Diagnosis and Treatment. Curr Pharm Des 17(25): 2595-602 (2011).
54. Espinoza M, de Silva R, Dickson DW, Davies P. Differential incorporation of tau isoforms in Alzheimer's disease. J Alzheimers Dis 14:1-16 (2008).
55. Glatz DC, Rujescu D, Tang Y, Berendt FJ, Hartmann AM, Faltraco F, et al. The alternative splicing of tau exon 10 and its regulatory proteins CLK2 and TRA2-BETA1 changes in sporadic Alzheimer's disease. J Neurochem 96: 635-44 (2006).
56. Di Luca M, Pastorino L, Bianchetti A, Perez J, Vignolo LA, Lenzi GL, et al. Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease. Arch Neurol 55:1195-200 (1998).
57. Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, et al. Cerebrospinal Fluid Levels of sAPPa and sAPPß in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. Int J Alzheimers Dis 2011: 495025 (2011).
58. Sanchez-Mejia RO, Newman JW, Toh S, Yu GQ, Zhou Y, Halabisky B, et al. Phospholipase A2 reduction ameliorates cognitive deficits in a mouse model of Alzheimer's disease. Nat Neurosci 11:1311-1318 (2008).
59. Caraci F, Bosco P, Signorelli M, Spada RS, Cosentino FI, Toscano G, et al. The CC genotype of transforming growth factor-ß1 increases the risk of late-onset Alzheimer's disease and is associated with AD-related depression. Eur Neuropsychopharmacol 22: 281-9 (2011).
60. Bi XH, Zhao HL, Zhang ZX, Zhang JW. PEMT G523A (V175M) Is Associated with Sporadic Alzheimer's Disease in a Chinese Population. J Mol Neurosci 46: 505-8 (2012).
61. Alexopoulos P, Guo LH, Kratzer M, Westerteicher C, Kurz A, Perneczky R. Impact of SORL1 Single Nucleotide Polymorphisms on Alzheimer's Disease Cerebrospinal Fluid Markers. Dement Geriatr Cogn Disord 32:164-170 (2011).
62. Hozumi I, Hasegawa T, Honda A, Ozawa K, Hayashi Y, Hashimoto K, et al. Patterns of levels of biological metals in CSF differ among neurodegenerative diseases. J Neurol Sci 303: 95-9 (2011).
63. Fuchs SA, Berger R, de Koning TJ. D-serine: the right or wrong isoform? Brain Res 1401: 104-17 (2011).